Search

Search Results

1. Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain

   Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric...

   Orr Shahar, Alexander Botvinnik, ... Tzuri Lifschytz in Molecular Psychiatry

   Article Open access 20 February 2024
   

2. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE)

   Synaptic vesicle glycoprotein-2 (SV2) is a family of proteins consisting of SV2A, SV2B, and SV2C. This protein family has attracted attention in...

   Burcu A. Pazarlar, Sanjay S. Aripaka, ... Jens D. Mikkelsen in Molecular Brain

   Article Open access 16 May 2022
   

3. Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson’s disease and dementia with Lewy bodies

   Regional differences in synaptic degeneration may underlie differences in clinical presentation and neuropathological disease progression in...

   Irene Frigerio, Maud M. A. Bouwman, ... Laura E. Jonkman in Acta Neuropathologica Communications

   Article Open access 03 January 2024
   

4. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats

   Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo.  Here, we...

   Ellis Chika Onwordi, Els F. Halff, ... Oliver D. Howes in Nature Communications

   Article Open access 14 January 2020
   

5. In vivo PET of synaptic density as potential diagnostic marker for cognitive disorders: prospective comparison with current imaging markers for neuronal dysfunction and relation to symptomatology - study protocol

   Background

   ¹⁸ F-FDG brain PET is clinically used for differential diagnosis in cognitive dysfunction of unclear etiology and for exclusion of a...

   Greet Vanderlinden, Charles Carron, ... Koen Van Laere in BMC Medical Imaging

   Article Open access 12 February 2024

6. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy

   One third of patients with epilepsy will continue to have uncontrolled seizures despite treatment with antiseizure medications (ASMs). There is...

   Pavel Klein, Dimitrios Bourikas in Advances in Therapy

   Article Open access 29 May 2024
   

7. Feasibility of imaging synaptic density in the human spinal cord using [¹¹C]UCB-J PET

   Purpose

   Neuronal damage and synapse loss in the spinal cord (SC) have been implicated in spinal cord injury (SCI) and neurodegenerative disorders such...

   Samantha Rossano, Takuya Toyonaga, ... Richard E. Carson in EJNMMI Physics

   Article Open access 03 May 2022
   

8. Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy

   Background

   Antiseizure medication (ASM) as monotherapy or in combination is the treatment of choice for most patients with epilepsy. Therefore,...

   Laurent M. Willems, Milena van der Goten, ... Adam Strzelczyk in CNS Drugs

   Article Open access 04 June 2023
   

9. Improved synthesis of SV2A targeting radiotracer [¹¹C]UCB-J

   Introduction

   [ ¹¹ C]UCB-J is a tracer developed for PET (positron emission tomography) that has high affinity towards synaptic vesicle glycoprotein 2A...

   Johanna Rokka, Eva Schlein, Jonas Eriksson in EJNMMI Radiopharmacy and Chemistry

   Article Open access 29 November 2019

10. Synergistic effects of vagus nerve stimulation and antiseizure medication

    Introduction

    Vagus nerve stimulation (VNS) is an effective, non-pharmacological therapy for epileptic seizures. Until now, favorable combinations of...

    Yaroslav Winter, Katharina Sandner, ... Sergiu Groppa in Journal of Neurology

    Article Open access 27 June 2023

11. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes

    Over the last five decades, a large body of evidence has accrued for structural and metabolic brain alterations in schizophrenia. Here we provide an...

    Oliver D. Howes, Connor Cummings, ... Ekaterina Shatalina in Neuropsychopharmacology

    Article Open access 02 September 2022
    

12. Exploring with [¹⁸F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy

    Purpose

    The main purpose of this study was to understand how the positron emission tomography (PET) measure of the synaptic vesicle 2A (SV2A) protein...

    Maria Elisa Serrano, Mohamed Ali Bahri, ... Alain Plenevaux in Molecular Imaging and Biology

    Article Open access 23 March 2020
    

13. What Is Neurodegeneration?

    Neurodegeneration is a progressive and irreversible process of structural and/or functional loss in neuronal cells, which affects vulnerable cell...

    Burcu Zeydan, Kejal Kantarci in Molecular Imaging of Neurodegenerative Disorders

    Chapter 2023
    

14. Potential of [¹¹C]UCB-J as a PET tracer for islets of Langerhans

    Biomarkers for the measurement of islets of Langerhans could help elucidate the etiology of diabetes. Synaptic vesicle glycoprotein 2 A (SV2A) is a...

    Emmi Puuvuori, Johanna Rokka, ... Olof Eriksson in Scientific Reports

    Article Open access 28 December 2021
    

15. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [¹⁸F]SDM-16

    Purpose

    To quantify the synaptic vesicle glycoprotein 2A (SV2A) changes in the whole central nervous system (CNS) under pathophysiological conditions,...

    Chao Zheng, Daniel Holden, ... Zhengxin Cai in European Journal of Nuclear Medicine and Molecular Imaging

    Article Open access 11 November 2021
    

16. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease

    Background

    Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence...

    Christopher H. van Dyck, Adam P. Mecca, ... Richard E. Carson in Alzheimer's Research & Therapy

    Article Open access 25 January 2024
    

17. Synaptic loss and its association with symptom severity in Parkinson’s disease

    Parkinson’s disease (PD) is the fastest growing neurodegenerative disease, but at present there is no cure, nor any disease-modifying treatments....

    Sophie E. Holmes, Praveen Honhar, ... David Matuskey in npj Parkinson's Disease

    Article Open access 24 February 2024
    

18. PET Imaging of Synaptic Vesicle Protein 2A

    The synaptic vesicle protein 2A (SV2A) is an integral 12-transmembrane domain glycoprotein located in the membrane of synaptic vesicles and widely...

    Sjoerd J. Finnema, Songye Li, ... Richard E. Carson in PET and SPECT of Neurobiological Systems

    Chapter 2021
    

19. Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature

    Background

    An increasing use of newer antiseizure medication (ASM) such as SV2A ligand brivaracetam is observed. However, data on newer antiseizure...

    Wiebke Hahn, Leona Möller, ... Susanne Knake in Neurological Research and Practice

    Article Open access 21 March 2024

20. Reductions in Synaptic Vesicle Glycoprotein 2 Isoforms in the Cortex and Hippocampus in a Rat Model of Traumatic Brain Injury

    Traumatic brain injury (TBI) can produce lasting cognitive, emotional, and somatic difficulties that can impact quality of life for patients living...

    Katherine M. Fronczak, Youming Li, ... Shaun W. Carlson in Molecular Neurobiology

    Article 25 August 2021